Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markersFull analysis of Phase 2 ...

China: A recent prospective cohort study has revealed that obesity significantly reduces the effectiveness of ...

Alcohol use disorder is a prevalent and major but preventable cause of morbidity and mortality worldwide, causing several ...

The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for ...

The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...

You'd think the sight of a new MG might attract more attention ... our final stop in the country, about 40 miles to the south of Dunnet Head, mainland Scotland’s northernmost point.

SAN FRANCISCO — Most patients with moderately to severely active Crohn’s disease who achieved endoscopic response and remission after 52 weeks of Omvoh therapy maintained those results through ...

Als MG vor gut sechs Jahren den Relaunch auf dem europäischen Markt einläutete, hätten sich viele sicher emotionalere und aufregendere Fahrzeuge gewünscht als die wenig spannend gestylten SUVs ...

A suspension of pantoprazole 2 mg/mL was prepared by triturating 20 40-mg tablets of pantoprazole,a mixing with sterile water for irrigationb and sodium bicarbonate,c and diluting to a final ...

Median time to remission was 24 weeks and median dose in remission was 30 mg. No significant safety issues were identified although tolerability appeared to decline above a dose of 40 mg with 26% ...